The serum lathosterol to cholesterol ratio, an index of cholesterol synthesis, is not elevated in patients with glomerular proteinuria and is not associated with improvement of hyperlipidemia in response to antiproteinuric treatment

Metabolism: Clinical and Experimental

Volumn 45, Issue 6, 1996, Pages 723-730

  Dullaart, Robin P F ^a   Gansevoort, Ron T ^a   Sluiter, Wim J ^a   De Zeeuw, Dick ^a   De Jong, Paul E ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LATHOSTEROL; SATURATED FATTY ACID; SERUM ALBUMIN; VERY LOW DENSITY LIPOPROTEIN;

ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CLINICAL ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; ENZYME ACTIVITY; GLOMERULUS FILTRATION; HUMAN; HYPERLIPIDEMIA; KIDNEY BIOPSY; NEPHROTIC SYNDROME; PRIORITY JOURNAL; PROTEINURIA; STATISTICAL ANALYSIS;

EID: 0029973274     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(96)90138-9     Document Type: Article

References (49)

1. Appel GB, Blum CB, Chien S, et al: The hyperlipidemia of the nephrotic syndrome. Relation to plasma albumin concentration, oncotic pressure, and viscosity. N Engl J Med 312:1544-1548, 1985
2. Kaysen GA, Myers BD, Couser WG, et al: Mechanisms and consequences of proteinuria. Lab Invest 54:479-498, 1986
3. Joven J, Villabona C, Villella E, et al: Abnormalities of lipoprotein metabolism in patients with the nephrotic syndrome. N Engl J Med 323:579-584, 1990
4. Keane WF, Kasiske BL: Hyperlipidemia in the nephrotic syndrome. N Engl J Med 323:603-604, 1990
5. Short CD, Durrington PN: Hyperlipidaemia and renal disease. Balliere's Clin Endocrinol Metab 4:777-806, 1990
6. Wanner C, Rader D, Bartens W, et al: Elevated plasma lipoprotein (a) in patients with the nephrotic syndrome. Ann Intern Med 119:263-269, 1993
7. Wanner C, Bartens W: Lipoprotein (a) in renal patients: Is it a key factor in the high cardiovascular mortality? Nephrol Dial Transplant 9:1066-1068, 1994
8. Ordonez JD, Hiatt RA, Killebrew EJ, et al: The increased risk of coronary heart disease associated with nephrotic syndrome. Kidney Int 44:638-642, 1993
9. Kaysen GA, Gambertoglio J, Felts J, et al: Albumin synthesis, albuminuria and hyperlipemia in nephrotic patients. Kidney Int 31:1368-1376, 1987
10. Marsh JB, Sparks CE: Hepatic secretion of lipoproteins in the rat and the effect of experimental nephrosis. J Clin Invest 64:1229-1237, 1979
11. Shafrir E, Brenner T: Lipoprotein lipid and protein synthesis in experimental nephrosis and plasmapheresis. I. Studies in rat in vivo. Lipids 14:695-702, 1979
12. Marsh JB: Lipoprotein metabolism in experimental nephrosis. J Lipid Res 25:1619-1623, 1984
13. Golper TA, Feingold KR, Fulford MH, et al: The role of circulating mevalonate in nephrotic hypercholesterolemia in the rat. J Lipid Res 27:1044-1051, 1986
14. McKenzie IFC, Nestel PJ: Studies on the turnover of triglycerides and esterified cholesterol in subjects with the nephrotic syndrome. J Clin Invest 47:1685-1695, 1968
15. Björkhem I, Miettinen T, Reihnér E, et al: Correlation between serum levels of some cholesterol precursors and activity of HMG-CoA reductase in human liver. J Lipid Res 28:1137-1143, 1987
16. Van Kempen HJM, Glatz JFC, Gevers Leuven JA, et al: Serum lathosterol concentration is an indicator of whole-body cholesterol synthesis in humans. J Lipid Res 29:1149-1155, 1988
17. Gylling H, Kuusi T, Vanhanen H, et al: Apolipoprotein E phenotype and cholesterol in familial hypercholesterolemia. Atherosclerosis 80:27-32, 1989
18. Miettinen TA, Tilvis RS, Kesāniemi YA: Serum plant sterols and cholesterol precursors reflect cholesterol absorption and synthesis in volunteers of a randomly selected male population. Am J Epidemiol 131:20-31, 1990
19. Wolthers BG, Waldrecht HT, Van der Molen JL, et al: Use of determinations of 7-lathosterol (5α-cholest-7-en-3β-ol) and other cholesterol precursors in serum in the study and treatment of disturbances of sterol metabolism, particularly cerebrotendinous xanthomatosis. J Lipid Res 32:603-612, 1991
20. Uusitupa MIJ, Miettinen TA, Happonen P, et al: Lathosterol and other noncholesterol sterols during treatment of hypercholesterolemia with lovastatin alone and with cholestyramine or guar gum. Arterioscler Thromb 12:807-813, 1992
21. Vanhanen H, Kesāniemi YA, Miettinen TA: Pravastatin lowers serum cholesterol, cholesterol-precursor sterols, fecal steroids, and cholesterol absorption in man. Metabolism 41:588-595, 1992
22. Lund E, Sisfontes L, Reihner E, et al: Determination of serum levels of unesterified lathosterol by isotope dilution-mass spectrometry. Scand J Clin Lab Invest 49:165-171, 1989
23. Elmberger PG, Kalén A, Lund E, et al: Effects of pravastatin and cholestyramine on products of the mevalonate pathway in familial hypercholesterolemia. J Lipid Res 32:935-940, 1991
24. Warwick GL, Packard CJ, Murray L, et al: Effect of simvastatin on plasma lipid and lipoprotein concentrations and low-density lipoprotein metabolism in the nephrotic syndrome. Clin Sci 82:701-708, 1992
25. Dullaart RPF, Gansevoort RT, Dikkeschei LD, et al: Role of elevated lecithin:cholesterol acyltransferase and cholesteryl ester transfer protein activities in abnormal lipoproteins from proteinuric patients. Kidney Int 44:91-97, 1993
26. Keilani T, Schlueter WA, Levin ML, et al: Improvement of lipid abnormalities associated with proteinuria using fosinopril, an angiotensin-converting enzyme inhibitor. Ann Intern Med 118:246-254, 1993
27. Gansevoort RT, Heeg JE, Dikkeschei LD, et al: Symptomatic antiproteinuric treatment decreases serum lipoprotein (a) concentration in patients with glomerular proteinuria. Nephrol Dial Transplant 9:244-250, 1994
28. De Zeeuw D, Gansevoort RT, Dullaart RPF, et al: Angiotensin II antagonism improves the lipoprotein profile in patients with nephrotic syndrome. J Hypertens 13:S53-S58, 1995 (suppl 1)
29. Gansevoort RT, De Zeeuw D, De Jong PE: Additive antiproteinuric effect of ACE inhibition and a low protein diet in human renal disease. Nephrol Dial Transplant 10:497-504, 1995
30. Stichting Nederlands voedingsstoffen bestand (NEVO) Centraal Onstituut voedingsonderzoeh Institute Toegepast Natuurwetenschappelȳk Onderzoeh. NEVO Table Zeist. Voorlichtingsbureau voor de voeding, 1987
31. Maroni BJ, Steinman TI, Mitch WE: A method for estimating nitrogen intake of patients with chronic renal failure. Kidney Int 27:58-65, 1985
32. Demacker PNM, Hijmans AOM, Vos-Janssen HF, et al: A study of the use of polyethylene glycol on estimating cholesterol in high density lipoprotein. Clin Chem 26:1775-1779, 1980
33. Dagen MM, Packard CJ, Shepherd J: A comparison of commercial kits for the measurement of lipoprotein (a). Ann Clin Biochem 20:359-364, 1991
34. Watanabe N, Kamei S, Ohkubo A, et al: Urinary protein as measured with pyrogallol red-molybdate complex, manually and in a Hitachi 726 automated analyzer. Clin Chem 32:1551-1554, 1986
35. Bilheimer DW, Stone NJ, Grundy SM: Metabolic studies in familial hypercholesterolemia. Evidence for a gene-dosage effect in vivo. J Clin Invest 64:524-533, 1979
36. Turley SD, Spady DK, Dietschy JM: Role of liver in the synthesis of cholesterol and the clearance of low density lipoproteins in the cynomolgus monkey. J Lipid Res 36:67-79, 1995
37. Dietschy JM, Turley SD, Spady DK: Role of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans. J Lipid Res 34:1637-1659, 1993
38. Tarugi P, Nicolini S, Albertazzi L, et al: Dyslipoproteinemia in an inbred strain with spontaneous chronic progressive nephrotic syndrome. J Lipid Res 32:1675-1687, 1991
39. Sun X, Jones H, Joles JA, et al: Apolipoprotein gene expression in analbuminemic rats and in rats with Heymann nephritis. Am J Physiol 262:F755-F761, 1992
40. Vega GL, Grundy SM: Lovastatin therapy in nephrotic hyperlipidemia: Effects on lipoprotein metabolism. Kidney Int 33:1160-1168, 1988
41. Warwick GL, Caslake MJ, Boulton-Jones JM, et al: Lowdensity lipoprotein metabolism in the nephrotic syndrome. Metabolism 39:187-192, 1990
42. Warwick GL, Packard CJ, Demant T, et al: Metabolism of apolipoprotein B-containing lipoproteins in subjects with nephroticrange proteinuria. Kidney Int 40:129-138, 1991
43. Babiak J, Rudel L: Lipoproteins and atherosclerosis. Baillière's Clin Endocrinol Metab 1:515-550, 1987
44. Davies WR, Staprans I, Hutchison FN, et al: Proteinuria, not altered albumin metabolism, affects hyperlipidemia in the nephrotic rat. J Clin Invest 86:500-505, 1990
45. Dullaart RPF, Groener JEM, Erkelens DW: Cholesteryl ester transfer between lipoproteins. Diabetes Nutr Metab 4:329-343, 1991
46. Moulin P, Appel GB, Ginsberg HN, et al: Increased concentration of plasma cholesteryl ester transfer protein in nephrotic syndrome: Role in dyslipidemia. J Lipid Res 33:1817-1822, 1992
47. Miettinen TA, Gylling H, Vanhanen H, et al: Cholesterol absorption, elimination, and synthesis related to LDL kinetics during varying fat intake in men with different apolipoprotein E phenotypes. Arterioscler Thromb 12:1044-1052, 1992
48. Glatz JFC, Katan MB: Dietary saturated fatty acids increase cholesterol synthesis and faecal steroid excretion in healthy men and women. Eur J Clin Invest 23:648-655, 1993
49. Zo eet Nederland, 1992. Resultaten van de voedselconsumptiepeiling 1992. Ministerie van Welzijn, Volksgezondheid en Cultuur, Ministerie van Landbouw, Natuurbeheer en Visserij. Den Haag. Voorlichtingsbureau voor de voeding, 1993